Myriad Genetics Announces Five Scientific Presentations At The 2017 American College Of Medical Genetics Annual Clinical Genetics Meeting

Published: Mar 20, 2017

New Data Will Highlight Advances in Genetic Variant Classification for Hereditary Cancers

SALT LAKE CITY, Utah, March 20, 2017 – Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and personalized medicine, today announced that the company will present five scientific posters at the 2017 American College of Medical Genetics Annual Clinical Genetics Meeting in Phoenix, Az. The presentations will highlight new data on variant classification and hereditary cancer syndromes.

“As genetic testing for hereditary cancer syndromes increases, we are generating tremendous volumes of data and identifying new genetic variants every day. Our highest priority is making sure patients and their families get accurate test results, which demands years of variant classification experience,” said Johnathan Lancaster, M.D., Ph.D., chief medical officer, Myriad Genetic Laboratories. “Myriad has been the leader in variant classification for more than 25 years, making us the most experienced commercial lab in the industry. Our passion for helping patients continues, and we are very excited to be presenting five new cutting-edge studies at ACMG that advance the science of variant classification.” The poster abstracts are now available here. Follow Myriad on Twitter via @MyriadGenetics to stay informed about news and updates from the Company.

Featured Poster Presentations

• Title: A significant proportion of TP53 pathogenic variants detected with a hereditary pan-cancer NGS panel are somatically acquired.
Date: Thursday, March 23, 2017: 10:00–11:30 a.m. MST.
Location: Poster 173.
Presenter: Bradford Coffee.

• Title: Complexities in hereditary cancer variant classification: Three case examples.
Date: Friday, March 24, 2017: 10:30–12:00 a.m. MST.
Location: Poster 154.
Presenter: Erin Mundt.

• Title: Case report: Sub-clinical Fanconi Anemia in siblings with bi-allelic BRIP1 mutations.
Date: Friday, March 24, 2017: 10:30–12:00 a.m. MST.
Location: Poster 378.
Presenter: Jamie Willmott.

• Title: Prevalence and characterization of triplications in genes associated with hereditary cancers.
Date: Friday, March 24, 2017: 10:30–12:00 a.m. MST.
Location: Poster 148.
Presenter: Heather LaBreche.

• Title: Apparent gene conversion event detected in CHEK2 using next generation sequencing analysis.
Date: Friday, March 24, 2017: 10:30–12:00 a.m. MST.
Location: Poster 156.
Presenter: Shujuan Pan.

About Myriad Genetics

Myriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on three strategic imperatives: transitioning and expanding its hereditary cancer testing markets, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets. For more information on how Myriad is making a difference, please visit the Company's website:

Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice HRD, EndoPredict, Vectra, GeneSight and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G.

Back to news